ClinicalTrials.gg
RecruitingNCT07847463HYSTERESISUpdated Sep 29, 2026

Can Exercise Electrocardiography Discriminate Hypertensive Heart Disease From Obstructive Coronary Artery Disease? A Multimodality Imaging Study

An observational study in Obstructive Coronary Artery Disease and Left Ventricular Hypertrophy, sponsored by University of Pisa. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Pisa · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertrophy, Left Ventricular with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hypertrophy, Left Ventricular · Italy.

Started
2026
with 1 other
Observational
2 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Hypertrophy, Left Ventricular with a site in Italy, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 14th registered.

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

Browse Hypertrophy, Left Ventricular studies →

Open to participants now

3 of the 14 studies in Hypertrophy, Left Ventricular with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 20 Hypertrophy, Left Ventricular studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertrophy, Left Ventricular with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the ability of exercise ECG to discriminate between hypertensive heart disease-related and CAD-related abnormalities

Read the detailed description

In this prospective study, consecutive patients undergoing evaluation for suspected coronary artery disease will undergo exercise ECG testing (ExECG), transthoracic echocardiography (TTE), stress cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA).

Patients will be stratified into four groups according to the presence or absence of LVH and obstructive CAD:

LVH with obstructive CAD LVH without obstructive CAD No LVH with obstructive CAD No LVH without obstructive CAD

LVH will be defined by standard echocardiographic criteria, while obstructive CAD will be assessed by CCTA. Stress CMR will serve as the reference standard for inducible myocardial ischemia.

Exercise ECG parameters will include conventional ST-segment criteria as well as dynamic indices during exercise and recovery. Associations between ECG findings and imaging-defined phenotypes will be evaluated, and predictors of CAD-related ischemia will be identified.

Results The study will assess the diagnostic performance of exercise ECG across the four predefined groups. Differences in ECG response patterns will be compared according to the presence of LVH and obstructive CAD. Multivariable analysis will be performed to identify independent ECG predictors associated with obstructive CAD and inducible ischemia.

03

Conditions studied

  • Obstructive Coronary Artery Disease
  • Left Ventricular Hypertrophy

Keywords

  • exercise ECG
  • LVH
  • CCTA
  • Stress CMR
  • CAD
  • transthoracic echocardiography
  • TTE
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

consecutive patients undergoing evaluation for suspected coronary artery disease will undergo exercise ECG testing (ExECG), transthoracic echocardiography (TTE), stress cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA).

Patients will be stratified into four groups according to the presence or absence of LVH and obstructive CAD:

LVH with obstructive CAD LVH without obstructive CAD No LVH with obstructive CAD No LVH without obstructive CAD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with CAD and LVH

Exclusion criteria

Exclusion Criteria:

  • Patients with RBBB
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • LVH with obstructive CAD

    LVH with obstructive CAD

  • LVH without obstructive CAD

    LVH without obstructive CAD

  • No LVH with obstructive CAD

    No LVH with obstructive CAD

  • No LVH without obstructive CAD

    No LVH without obstructive CAD

06

What researchers measure

Primary outcomes

  1. diagnostic performance of exercise ECG across the four predefined groups.

    Differences in ECG response patterns will be compared according to the presence of LVH and obstructive CAD. Multivariable analysis will be performed to identify independent ECG predictors associated with obstructive CAD and inducible ischemia.

    Time frame: From enrollment through completion of all diagnostic evaluations, assessed up to 3 months after enrollment.

07

Study locations

1 of 1 sites recruiting
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, PI 56124, Italy
    Recruiting
    • Mattia Alberti, MD, PhD candidate · Contactmattia.alberti@phd.unipi.it · +39 3770805335
    • Morrone Doralisa, MD, PhD, Associate Professor · Contactdoralisa.morrone@unipi.it
    • Riccardo Canonaco, MD · Sub investigator
    • Simona Chiusolo, MD · Sub investigator
    • Simona Buralli, MD · Sub investigator
    • Stefano Taddei, MD, Full Professor · Sub investigator
    • Emanuele Neri, MD, Full Professor · Sub investigator
    • Giovanni Donato Aquaro, MD, PhD, Associate Professor · Sub investigator
    • Lorenzo Faggioni, MD, Associate Professor · Sub investigator
    • Doralisa Morrone, MD, PhD, Associate Professor · Sub investigator
    • Raffaele De Caterina, MD, PhD, Full Professor · Sub investigator
    • Pietro Lucii, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will be made available upon reasonable request following the completion of all planned analyses and subsequent publication of the resulting manuscripts

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 18 observational studies under Hypertrophy, Left Ventricular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 58. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 29, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847463
Lead sponsor
University of Pisa
Responsible party
Mattia Alberti (MD, PhDs, University of Pisa) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion